Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 14,113 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Completed Phase 3 Interventional

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant

NCT02610296
View directory record Official record
Conditions
Delayed Graft Function
Interventions
QPI-1002, Placebo
Drug · Other
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

NCT05686408
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major, Depressive Episode, Depression Severe
Interventions
TNX-601 ER, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
27
States / cities
Little Rock, Arkansas • Bellflower, California • Glendale, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 2 Interventional

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

NCT00290940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CS-917, metformin hydrochloride, pioglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2007 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity

NCT06680440
View directory record Official record
Conditions
Weight Management
Interventions
ASC30, Placebo
Drug · Other
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 30, 2026, 2:02 PM EDT
Terminated Not applicable Interventional Results available

Arthrex Eclipse™ Shoulder Prosthesis

NCT01790113
View directory record Official record
Conditions
Osteoarthritis
Interventions
Univers™, Eclipse™ Total Shoulder Replacement
Device
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
21 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
16
States / cities
Sun City, Arizona • Redwood City, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Not applicable Interventional Results available

Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan

NCT00683020
View directory record Official record
Conditions
Diabetes
Interventions
ATSM Intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy

NCT01675882
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg, Viaskin Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 55 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

NCT06019559
View directory record Official record
Conditions
Obesity
Interventions
K-757 120 mg BID and K-833 100 mg BID, K-757 120 mg BID and matching placebo to K-833, Matching placebo to K-757 and matching placebo to K-833
Drug
Lead sponsor
TriGemX Bio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
San Diego, California • Stockbridge, Georgia • Topeka, Kansas + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

NCT05244980
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Diego, California • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 30, 2026, 2:02 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration

NCT02398500
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
LMG324, Ranibizumab 0.5 mg, Sham
Biological
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.

NCT00453687
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK233705
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

NCT04091087
View directory record Official record
Conditions
Stasis Dermatitis
Interventions
crisaborole ointment, vehicle ointment
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
El Segundo, California • Lafayette, California • South San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03103087
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT05274750
View directory record Official record
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

NCT00145574
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
colesevelam HCl, placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
10 Years to 17 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
8
States / cities
Washington D.C., District of Columbia • St Louis, Missouri • New Hyde Park, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients

NCT01841996
View directory record Official record
Conditions
Onychomycosis
Interventions
ME1111 solution, Vehicle Solution
Drug
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT02073279
View directory record Official record
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions
Satralizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
20
States / cities
Aurora, Colorado • Miami, Florida • Vero Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

NCT05845996
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SAR441344, placebo, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Not applicable Interventional

Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.

NCT04828668
View directory record Official record
Conditions
Covid 19
Interventions
Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)
Dietary Supplement
Lead sponsor
Endourage, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple Hollowing in Adult Participants ≥ 22 Years Old

NCT04414397
View directory record Official record
Conditions
Temple Hollowing
Interventions
JUVÉDERM® VOLUMA® XC, No-treatment control
Device · Other
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

NCT03987620
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
21
States / cities
Mesa, Arizona • Lakewood, Colorado • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

NCT03945279
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB100, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 30, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis

NCT00440518
View directory record Official record
Conditions
Migraine
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
24
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Walnut Creek, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 30, 2026, 2:02 PM EDT
Terminated Phase 3 Interventional

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

NCT05964413
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
vilobelimab, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Hialeah, Florida • Miami, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 30, 2026, 2:02 PM EDT